Avalyn Pharma Inc.

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Its pipeline features optimized inhaled formulations of established antifibrotic medicines, such as AP01, an inhaled version of pirfenidone for progressive pulmonary fibrosis, and AP02, an inhaled formulation of nintedanib for idiopathic pulmonary fibrosis. This nebulization approach aims to deliver medication directly to the lung tissue, potentially improving efficacy while reducing the significant side effects and tolerability issues associated with current oral therapies that often limit patient compliance. Avalyn Pharma Inc. focuses on addressing the unmet needs in treating these progressive conditions by enhancing local drug delivery and minimizing systemic exposure. Founded in 2011 and headquartered in Boston, Massachusetts, the company operates in the biopharmaceutical sector targeting serious rare lung disorders.

Sector

Healthcare

Industry

Biotechnology

CEO

Ms. Lyn Baranowski

Employees

50

Headquarters

Boston, MA, United States

Website

www.avalynpharma.com